Cramer Remix: Memo to Apple CEO Tim Cook

Apple was once known as the stock that couldn't stop climbing higher. But these days the prevailing wisdom is that the stock is stalled, and there is no way it will have higher numbers in 2016 than this year. So, what should CEO Tim Cook do? Jim Cramer has a plan.

"Many professional investors have come to believe that Apple cannot maintain its earnings momentum because it doesn't have enough large streams of recurring, higher-margin revenue to offset what could be a slowdown in iPhone sales," the "Mad Money" host said.

With this in mind, Cramer reminded investors that he doesn't think Cook should worry. Apple has done incredibly well under his management, and Cramer thinks it will continue to do so.

But if Cramer were Cook, he would take the initiative to buy four companies.

With just $25 billion, Apple could get Harman, Pandora, Fitbit and Verifone. All of these companies would give investors a recurring reason to own the stock in 2016 besides just an iPhone.

"Honestly, it makes so much sense I can't believe they haven't thought of it themselves!" Cramer said.

Read MoreCramer: What Apple must do to skyrocket in 2016

Cramer welcomed investors back to Crazy Town on Tuesday. That is the strange world of the market lately where everyone is doing everything wrong. They are buying the wrong stocks, reaching the wrong conclusions and taking the wrong risks.

And it is all oil's fault.

In Cramer's opinion, investors are worshiping a false god of higher oil. Thus, even the slightest rise in crude prices allows stocks to go higher. To explain the crazy linkage between higher oil and stocks, Cramer shared three reasons why stocks tend to rally when the price of crude goes up.

When oil goes higher, it takes the heat off of the massive meltdown of the master limited partnerships (MLP) and pipeline plays. These are companies that investors often buy because of their high dividends, not growth.

"Put simply, this group has been one of the great disasters of the era. I cannot believe how poorly they have performed," Cramer said.(Tweet This)

Read More Cramer: The greatest disaster of our era

Additionally, the strong dollar has a significant impact on the market because it makes U.S. international companies less competitive overseas. Meanwhile, the ultralow price of oil has many oil companies in dire straits and doesn't seem to be benefiting consumers as it should.

And while the price of crude has been totally pulverized by oversupply, it is also a currency issue. Crude is priced in dollars, which means that when it gets stronger oil gets weaker.

"This relationship between currency and oil often gets overlooked," the "Mad Money" host said. (Tweet This)

To get a better read on where oil and currency could be headed, Cramer spoke with Carley Garner, a technician and commodities expert who co-founded DeCarley Trading and a colleague of Cramer's at

Because the price of crude is so heavily influenced by the strong dollar, Garner found that oil and the euro often trade in lockstep with one another. There is a high correlation between the two because they are both punished when the dollar increases in value.

In Garner's opinion, both oil and the euro could be closer to a bottom than most people think. In fact, she thinks the euro could have bottomed already.

Read MoreCramer: Big oil rebound coming, thanks to the euro

Another winner from last week's Federal Reserve rate hike is Paychex, the No. 2 payroll processor in the U.S., which focuses on small to medium sized businesses and has a strong human resources and benefits outsourcing division.

Paychex sits on large piles of cash for short periods of time because there is a lag between the times that the company pays out on the cash for its payroll budget, and when a paycheck is deposited. Paychex collects interest on that money, known as the float; now that rates are going higher, it will collect more interest.

To learn more about what could be in store for the future Paychex, Cramer spoke with CEO Marty Mucci, who commented in the impact of rising rates.

"Every 1 percent increase is about $20 million on an annual basis. So, this first quarter point is worth on an annual basis about $4 to $5 million basically to the bottom line for us," Mucci said.

Cramer always has his eye out for speculative biotech companies that have the potential to be a game-changer.

"These early stage biotechs are very high risk — you wouldn't want to own them in your retirement fund — but if everything goes right, admittedly a big if, then the rewards can be enormous," Cramer said.

Cellectis is a French biotech that started trading in the U.S. in March. It has been a pioneer in the area of DNA genome engineering, meaning it basically edits DNA to add or remove sequences to reprogram a cell. Cellectis is also using this technology to fight cancer by engineering T-cells.

To learn more, Cramer spoke with the company's chairman and CEO, Dr. André Choulika, who commented on the company's partnership with Pfizer that began in January 2014.

"We have to team up with large players such as Pfizer in order to tackle such type of indications," Dr. Choulika said.

In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:

Hain Celestial: "When the tax loss selling is over, you want to pull the trigger. I've got to tell you something, I see Whole Foods has bottomed."

Kansas City Southern: "No, I'd rather own Union Pacific."

Read MoreLightning Round: This stock has bottomed